The three independent studies, collected in a white paper by New Zealand-based Blis Technologies Ltd, provide evidence that the strain may reduce the frequency and length of respiratory illness.
“We always say that the mouth is the gateway to the body, and these studies help investigate the role that the oral microbiome plays in our overall health and immunity,”said John Hill, Ph.D., chief technology officer of Blis Technologies.
small bacterial bullets
Developed by scientists at the University of Otago in New Zealand, BLIS K12 is a specific strain patented by Salivary streptococcus (S. salivarius)It was first isolated from the mouth of a healthy child.
The commensal bacteria secrete powerful antimicrobial molecules, which the company describes as “Tiny Bacterial Lead That Inhibits Bad Bacteria”. These are referred to as bacteriocin inhibitory substances or simply BLIS.
“Daily consumption of BLIS K12 helps keep bad bacteria away, improving the body’s natural ability to defend against airborne germs and potential threats,”Hill explained.
Blis Technologies introduced the strain as a major ingredient in ThroatHealth lozenges in 2002, and it has been clinically shown to reduce the frequency of sore throats and tonsillitis by up to 90%. Since then, the company has established itself as a leader in oral health probiotics, adding two more patented strains – BLIS M18 Dental Health and BLIS Q24 Skin Health.
What is in the white paper?
The first study, developed by researchers in Italy, examined the incidence of Covid-19 in school-aged children. The randomized controlled trial gave a 90-day treatment to 128 participants and found that none of the 64 children who took BLIS K12 tested positive for Covid-19 compared to a 38% positivity rate in the group that didn’t take the probiotics.
These results appear to be conclusively consistent with the hypotheses established regarding: 1) the close association between oral microbiota and lung microbiota. 2) the possibility that oral microbiota not dominated by pathogenic or Gram-negative species favoring the formation of a lung microbiota is less likely to develop inflammatory responses to viruses; and 3) the notion that administering orally colonizing bacteria belonging to microbial consortia frequently found in people unaffected by Covid-19 prevents infection,” The study authors wrote.
Meanwhile, a Chinese study in Wuhan used BLIS K12 as a supplement in the treatment of recurrent upper respiratory tract infections (RRTi) in children during the cold season. The results showed that consuming BLIS K12 for 30 days, along with conventional treatments, reduced the recurrence rate from 34% to 15%. Children in the treatment group had shorter and milder symptoms, fewer absences from school, and less treatment with antibiotics and antivirals.
“The use of oropharyngeal probiotics as a complementary therapy to stabilize oropharyngeal bacteria, specifically inhibiting respiratory pathogens, could be a promising approach to reduce the burden of RRTi and combat long-term antibiotic resistance,”The study authors mentioned.
In the third study, 193 frontline healthcare workers in China consumed two BLIS K12 lozenges daily for one month to investigate the effect of probiotics on the prevalence and duration of respiratory infections. Researchers found that it reduced the frequency of respiratory infections by 64.8%, reduced the duration of respiratory infections and mouth ulcers by 78%, and reduced days of absence from work by 95.5%.
All three studies call for further research under more controlled conditions.
#Blis #Technologies #highlights #respiratory #health #benefits #oral #probiotics